EU nod for new formulation of Biogen's Tysabri
A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis
9th April 2021
A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis
9th April 2021
The combination is not considered to be a cost-effective use of NHS resources in this setting
9th April 2021
The drug was discovered through an AI-design platform within just eight months of project initiation
9th April 2021
The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
9th April 2021
The Cancer Research UK spinout is developing precision T cell therapies to treat multiple cancers
8th April 2021
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
8th April 2021
The risk of rare blood clots is currently calculated at four people in a million who receive the vaccine
8th April 2021
Data suggest infections in England fell by 60% from February, but the decline is levelling
8th April 2021
Supplies of Estradot TTS-75 are expected to return to normal within eight weeks
7th April 2021
The NIHR-funded trial will assess whether removing small fibroids and endometrial polyps improves fertility and live births
7th April 2021
The deal could be worth as much as $1.3 billion to Artios
7th April 2021
The £20 million fund will boost the UK's life sciences manufacturing capabilities, creating new economic opportunities and highly skilled jobs
7th April 2021
The vaccine is the third to be approved for use in the UK to protect against COVID-19
7th April 2021
The 2021 Communications Awards have opened their doors for entry, inviting the very best in pharma communications to come forward and claim first prize.
6th April 2021
Funding backed for reversal of gastrointestinal bleeds but not for intracranial haemorrhage
6th April 2021